JP2021524447A5 - - Google Patents
Info
- Publication number
- JP2021524447A5 JP2021524447A5 JP2020564476A JP2020564476A JP2021524447A5 JP 2021524447 A5 JP2021524447 A5 JP 2021524447A5 JP 2020564476 A JP2020564476 A JP 2020564476A JP 2020564476 A JP2020564476 A JP 2020564476A JP 2021524447 A5 JP2021524447 A5 JP 2021524447A5
- Authority
- JP
- Japan
- Prior art keywords
- linker
- residue
- immunoconjugate
- side chain
- nitrogen atom
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024026029A JP2024059814A (ja) | 2018-05-17 | 2024-02-22 | イムノコンジュゲート |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862673015P | 2018-05-17 | 2018-05-17 | |
| US62/673,015 | 2018-05-17 | ||
| US201862724259P | 2018-08-29 | 2018-08-29 | |
| US62/724,259 | 2018-08-29 | ||
| PCT/US2019/032947 WO2019222676A1 (en) | 2018-05-17 | 2019-05-17 | Immunoconjugates |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024026029A Division JP2024059814A (ja) | 2018-05-17 | 2024-02-22 | イムノコンジュゲート |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2021524447A JP2021524447A (ja) | 2021-09-13 |
| JP2021524447A5 true JP2021524447A5 (enExample) | 2022-05-23 |
Family
ID=66691077
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020564476A Pending JP2021524447A (ja) | 2018-05-17 | 2019-05-17 | イムノコンジュゲート |
| JP2024026029A Pending JP2024059814A (ja) | 2018-05-17 | 2024-02-22 | イムノコンジュゲート |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024026029A Pending JP2024059814A (ja) | 2018-05-17 | 2024-02-22 | イムノコンジュゲート |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20210154316A1 (enExample) |
| EP (1) | EP3793613B1 (enExample) |
| JP (2) | JP2021524447A (enExample) |
| KR (1) | KR20210013096A (enExample) |
| CN (1) | CN112153988A (enExample) |
| AU (1) | AU2019270178A1 (enExample) |
| CA (1) | CA3100544A1 (enExample) |
| ES (1) | ES3003787T3 (enExample) |
| IL (1) | IL278633B2 (enExample) |
| WO (1) | WO2019222676A1 (enExample) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109843327B (zh) | 2016-07-07 | 2022-05-13 | 小利兰·斯坦福大学托管委员会 | 抗体佐剂缀合物 |
| CA3110510A1 (en) * | 2018-08-29 | 2020-03-05 | Bolt Biotherapeutics, Inc. | Immunoconjugates targeting egfr |
| AU2019337654A1 (en) * | 2018-09-12 | 2021-04-08 | Silverback Therapeutics, Inc. | Substituted benzazepine compounds, conjugates, and uses thereof |
| US20220152215A1 (en) * | 2019-03-15 | 2022-05-19 | Bolt Biotherapeutics, Inc. | Immunoconjugates Targeting CEA |
| WO2020190731A1 (en) * | 2019-03-15 | 2020-09-24 | Bolt Biotherapeutics, Inc. | Immunoconjugates targeting her2 |
| US20220226491A1 (en) * | 2019-03-15 | 2022-07-21 | Bolt Biotherapeutics, Inc. | Immunoconjugates Targeting PD-L1 |
| WO2020190725A1 (en) * | 2019-03-15 | 2020-09-24 | Bolt Biotherapeutics, Inc. | Immunoconjugates targeting her2 |
| US20220143012A1 (en) * | 2019-03-15 | 2022-05-12 | Bolt Biotherapeutics, Inc. | Macromolecule-Supported TLR Agonists |
| EP4048314A1 (en) * | 2019-10-25 | 2022-08-31 | Bolt Biotherapeutics, Inc. | Macromolecule-supported thienoazepine compounds, and uses thereof |
| TWI857167B (zh) | 2019-10-25 | 2024-10-01 | 美商博特生物治療公司 | 噻吩并氮呯免疫結合物及其用途 |
| CA3169117A1 (en) * | 2020-02-25 | 2021-09-02 | Bolt Biotherapeutics, Inc. | Cancer treatment methods |
| US20230293716A1 (en) * | 2020-05-08 | 2023-09-21 | Bolt Biotherapeutics, Inc. | Elastase-substrate, peptide linker immunoconjugates, and uses thereof |
| CN113999313A (zh) * | 2020-07-28 | 2022-02-01 | 百奥泰生物制药股份有限公司 | 抗her2抗体及其应用 |
| IL300316A (en) * | 2020-08-13 | 2023-04-01 | Bolt Biotherapeutics Inc | Immune conjugates of pyrazolozapines and their uses |
| IL303350A (en) | 2020-12-04 | 2023-08-01 | Macrogenics Inc | Pharmaceutical compositions of a her2/neu antibody and use of the same |
| BR112023015561A2 (pt) * | 2021-02-03 | 2023-11-14 | Univ Minnesota | Compostos imunoestimuiladores e conjugados |
| KR102917231B1 (ko) * | 2021-03-08 | 2026-01-26 | 진콴텀 헬스케어 (쑤저우) 씨오., 엘티디. | 항체 면역 작용제 접합체 및 이의 적용 |
| EP4331616A4 (en) * | 2021-05-13 | 2026-03-18 | Univ Tsinghua | ANTIBODY-DRUG CONJUGATE, RELATED PREPARATION PROCESS AND ASSOCIATED USE |
| WO2023044016A2 (en) * | 2021-09-17 | 2023-03-23 | Cspc Dophen Corporation | Antibody immune-stimulant conjugates and use thereof |
| JP2024539993A (ja) | 2021-10-29 | 2024-10-31 | ボルト バイオセラピューティクス、インコーポレーテッド | システイン変異抗体を含むｔｌｒアゴニスト免疫複合体、及びその使用 |
| AU2023253036A1 (en) * | 2022-04-15 | 2024-10-17 | Mabsoft Therapeutics | Conjugate comprising toll-like receptor agonist |
| TW202540200A (zh) | 2023-12-01 | 2025-10-16 | 美商基利科學股份有限公司 | 抗ｆａｐ－ｌｉｇｈｔ融合蛋白及其用途 |
| WO2025259871A1 (en) | 2024-06-14 | 2025-12-18 | Gilead Sciences, Inc. | Anti-ccr8 antibodies and uses thereof |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP3101690B2 (ja) | 1987-03-18 | 2000-10-23 | エス・ビィ・２・インコーポレイテッド | 変性抗体の、または変性抗体に関する改良 |
| JP2003531149A (ja) | 2000-04-13 | 2003-10-21 | ザ・ロツクフエラー・ユニバーシテイ | 抗体由来の免疫応答の増強 |
| US20040101909A1 (en) | 2002-08-20 | 2004-05-27 | Hema-Quebec, 2535 Boul. Laurier, Ste-Foy, Quebec, Canada G1V 4M3 | Purification of polyreactive autoantibodies and uses thereof |
| US20070259907A1 (en) | 2004-06-18 | 2007-11-08 | Prince Ryan B | Aryl and arylalkylenyl substituted thiazoloquinolines and thiazolonaphthyridines |
| WO2006073921A2 (en) | 2004-12-30 | 2006-07-13 | The Rockefeller University | Compositions and methods for enhanced dendritic cell maturation and function |
| US8354249B2 (en) | 2005-08-11 | 2013-01-15 | Omrix Biopharmaceuticals Ltd. | Intravenous immunoglobulin composition |
| TW201402124A (zh) | 2005-08-19 | 2014-01-16 | Array Biopharma Inc | 作為類鐸受體（ｔｏｌｌ-ｌｉｋｅ ｒｅｃｅｐｔｏｒ）調節劑之８-經取代苯并氮雜呯 |
| CN101304748A (zh) | 2005-08-22 | 2008-11-12 | 加利福尼亚大学董事会 | Tlr激动剂 |
| US20080286819A1 (en) | 2005-11-07 | 2008-11-20 | Ravetch Jeffrey V | Reagents, Methods and Systems for Selecting a Cytotoxic Antibody or Variant Thereof |
| EP1988896A4 (en) * | 2006-02-22 | 2011-07-27 | 3M Innovative Properties Co | CONJUGATES TO MODIFY IMMUNE REACTIONS |
| US20100150942A1 (en) | 2008-12-03 | 2010-06-17 | Cantor Thomas L | Affinity purified human polyclonal antibodies and methods of making and using them |
| US20130108619A1 (en) | 2011-11-02 | 2013-05-02 | Isaac Melamed | Intravenous immunoglobulin processing, diagnostic, and treatment systems and methods |
| US20130177574A1 (en) | 2012-01-11 | 2013-07-11 | Paul I. Terasaki Foundation Laboratory | ANTI-HLA CLASS-Ib ANTIBODIES MIMIC IMMUNOREACTIVITY AND IMMUNOMODULATORY FUNCTIONS OF INTRAVENOUS IMMUNOGLOBULIN (IVIg) USEFUL AS THERAPEUTIC IVIg MIMETICS AND METHODS OF THEIR USE |
| BR112016014952A2 (pt) | 2014-02-10 | 2017-09-19 | Merck Patent Gmbh | Inibição direcionada de tgfbeta |
| AU2015349878A1 (en) | 2014-11-21 | 2017-05-25 | Bristol-Myers Squibb Company | Antibodies against CD73 and uses thereof |
| PT3265458T (pt) | 2015-03-06 | 2019-02-13 | Hoffmann La Roche | Compostos de dicarboxamida de benzazepina |
| US20170158772A1 (en) | 2015-12-07 | 2017-06-08 | Opi Vi - Ip Holdco Llc | Compositions of antibody construct - agonist conjugates and methods of use thereof |
| CN109843327B (zh) | 2016-07-07 | 2022-05-13 | 小利兰·斯坦福大学托管委员会 | 抗体佐剂缀合物 |
| US20190336615A1 (en) | 2017-01-27 | 2019-11-07 | Silverback Therapeutics, Inc. | Tumor targeting conjugates and methods of use thereof |
| SG10202110182PA (en) | 2017-03-15 | 2021-10-28 | Silverback Therapeutics Inc | Benzazepine compounds, conjugates, and uses thereof |
-
2019
- 2019-05-17 CA CA3100544A patent/CA3100544A1/en active Pending
- 2019-05-17 US US17/056,259 patent/US20210154316A1/en active Pending
- 2019-05-17 KR KR1020207036222A patent/KR20210013096A/ko not_active Ceased
- 2019-05-17 WO PCT/US2019/032947 patent/WO2019222676A1/en not_active Ceased
- 2019-05-17 AU AU2019270178A patent/AU2019270178A1/en not_active Abandoned
- 2019-05-17 CN CN201980032295.1A patent/CN112153988A/zh active Pending
- 2019-05-17 IL IL278633A patent/IL278633B2/en unknown
- 2019-05-17 EP EP19728294.0A patent/EP3793613B1/en active Active
- 2019-05-17 JP JP2020564476A patent/JP2021524447A/ja active Pending
- 2019-05-17 ES ES19728294T patent/ES3003787T3/es active Active
-
2024
- 2024-02-22 JP JP2024026029A patent/JP2024059814A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021524447A5 (enExample) | ||
| IL278633B1 (en) | Immunoconjugates | |
| JP2019520352A5 (enExample) | ||
| JP2019532056A5 (enExample) | ||
| JP2019536740A5 (enExample) | ||
| JP2021524267A5 (enExample) | ||
| US10428156B2 (en) | Anti-MFI2 antibodies and methods of use | |
| JP2019146572A5 (enExample) | ||
| JP2017534253A5 (enExample) | ||
| JP2016528882A5 (enExample) | ||
| JP2020531048A5 (enExample) | ||
| JP2014522850A5 (enExample) | ||
| JP2017535246A5 (enExample) | ||
| JP2012522513A5 (enExample) | ||
| KR20180088445A (ko) | 신규한 항-클라우딘 항체 및 사용 방법 | |
| KR20160097336A (ko) | 신규 항-ｄｐｅｐ3 항체 및 이의 사용 방법 | |
| JP2017536341A5 (enExample) | ||
| JP2016531915A5 (enExample) | ||
| JP2022533538A5 (enExample) | ||
| JP2021514973A5 (enExample) | ||
| JP2017522861A5 (enExample) | ||
| JP2018509182A5 (enExample) | ||
| RU2014146951A (ru) | Конъюгаты типа лиганд dr5-лекарственное средство | |
| KR20160070191A (ko) | 신규한 항-클라우딘 항체 및 사용 방법 | |
| JP2014526898A5 (enExample) |